ArticleBlood advances2024

Dual-targeting CD33/CD123 NANOBODY T-cell engager with potent anti-AML activity and good safety profile.

Zhihong Zeng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.